Stockscreener 앱 받기
1.73
0.58%
0.01
시간 외 거래:
1.73
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com
Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times
Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World
Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com
Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha
Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider
Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat
HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK
Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire
Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat
Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com
Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada
VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times
Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News
An analyst sees good growth prospects for Ventyx Biosciences Inc (VTYX) - SETE News
Sanofi Invests $27M in Ventyx Bio - San Diego Business Journal
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Ventyx Biosciences Inc (VTYX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Is Ventyx Biosciences Inc (VTYX) a good investment opportunity? - US Post News
Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex
Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News
VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN
Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex
Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat
Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle
Adversity is less terrifying than hope: Ventyx Biosciences Inc (VTYX) - SETE News
Ventyx Biosciences retains stock target, neutral rating despite Sanofi's $27M stake - Investing.com
Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences - MSN
Ventyx Biosciences Inc (VTYX) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Ventyx stock climbs 8% on $27M Sanofi investment - MSN
Thoughtworks (NASDAQ:TWKS) Sees Large Volume Increase - Defense World
VTYX’s Q2 earnings predictions: What the experts say - US Post News
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright - TipRanks
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M - Fierce Biotech
Victory Capital (NASDAQ:VCTR) Hits New 12-Month High at $56.29 - MarketBeat
0.93%
3.55%
자본화:
|
볼륨(24시간):